A study of repotrectinib versus crizotinib with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer, TRIDENT-3 [NCT06140836], is a phase three trial which started in December of 2023 [54]. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.